Zydus launches world’s first biosimilar of Humira

9 December 2014
biosimilars_samples_large

A biosimilar of AbbVie’s (NYSE: ABBV) blockbuster drug Humira (adalimumab) has been launched in India by generic drugmaker Zydus Cadila (NSE: CADILAHC).

The biosimilar has been approved by the Drug Controller General of India and will be marketed under the brand name Exemptia to treat autoimmune disorders such as rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, and ankylosing spondylitis.

AbbVie’s third quarter financial results revealed sales for Humira increased 17.5% from the previous year period to $3.26 billion, with US Humira sales rising 25.3% to $1.74 billion.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Companies featured in this story

More ones to watch >


Today's issue

Company Spotlight





More Features in Biosimilars